Searchable abstracts of presentations at key conferences in endocrinology

ea0026mte19 | (1) | ECE2011

Management of primary hyperparathyroidism

Bollerslev Jens

The clinical presentation of primary hyperparathyroidism (PHPT) has changed dramatically after increased accessibility to biochemical auto-analysers and the diagnosis is today often made by change in patients without specific symptoms. Operative treatment is recommended in patient with markedly increased calcium levels or typical symptoms. However, the vast majority of patients in the modern clinic do not present organ related symptoms and their calcium levels are only slightl...

ea0020s13.2 | Pro & con – Surgery for ‘asymptomatic’ hyperparathyroidism | ECE2009

Management of mild primary hyperparathyroidism

Bollerslev Jens

The clinical presentation of primary hyperparathyroidism has changed dramatically after increased accessibility to biochemical auto-analysers and the diagnosis is today often made by change in patients without specific symptoms. Operative treatment is recommended in patient with markedly increased calcium levels or typical symptoms. However, the vast majority of patients in the modern clinic do not present organ related symptoms and their calcium levels are only slightly incre...

ea0056s12.3 | Why do fractures occur in endocrine disorders, and how should they be handled? | ECE2018

Parathyroid dysfunctions – bone mass and fractures in primary hyperparathyroidism

Bollerslev Jens

Primary Hyperparathyroidism (PHPT) is the most common disease among parathyroid disorders compared to Chronic Hypoparathyroidism, Calcium Sensor disorders (loss or gain of function mutations) or Parathyroid Cancer. The clinical presentation of PHPT has changed dramatically after the increased accessibility to biochemical analyses. The diagnosis is today often made by change in patients without specific symptoms. Operative treatment is always an option and recommended in patien...

ea0049gp155 | Neuroendocrinology & Growth Hormones | ECE2017

A novel purified polyclonal antibody towards T-Pit is a reliable marker of corticotroph cell differentiation

Sjostedt Evelina , Bollerslev Jens , Ponten Fredrik , Casar-Borota Olivera

Classification of pituitary neuroendocrine tumours (NETs) or pituitary adenomas is based on the expression of the anterior lobe pituitary hormones (FSH, LH, GH, Prolactin, TSH, ACTH and alpha-subunit of the glycoprotein hormones). Assessment of the transcription factors SF-1, Pit-1 and T-Pit has been a complement to the classification. Tumours negative for both pituitary hormones and transcription factors have been designated as null-cell adenomas. However, lack of sensitive a...

ea0041gp150 | Pituitary - Clinical | ECE2016

Treatment of acromegaly increases BMD but reduces Trabecular Bone Score – a longitudinal study

Godang Kristin , Cristina Olarescu Nicoleta , Bollerslev Jens , Heck Ansgar

Background: Bone turnover is increased in active acromegaly. Despite normalization of bone turnover after treatment, the risk for vertebral fractures remains increased. Gonadal status, but not bone mineral density (BMD) is correlated to vertebral fracture incidence. Trabecular and cortical bone are differentially affected by GH and IGF-1. The trabecular bone score (TBS) is related to bone microarchitecture and provides further information not captured by BMD measurement.<p...

ea0020p595 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Growth hormone replacement therapy in adult onset growth hormone deficiency induces favorable long-term effects on quality of life, bone, body composition and lipids: a 55 month prospective study

Jorgensen Anders Palmstrom , Fougner Krisitan J , Schreiner Thomas , Bollerslev Jens

Objective: To investigate long-term effects of GH replacement therapy.Material and methods: Thirty-nine patients (mean age 52.5 years, 14 women) with adult-onset growth hormone deficiency (AOGHD), recruited from a randomized placebo-controlled crossover study of treatment with growth hormone (GH) and placebo for 9months each, were enrolled in an open prospective follow up study. GH replacement was given for additional thirty-three months and was individu...

ea0081ep775 | Pituitary and Neuroendocrinology | ECE2022

Distribution of E- and N-cadherin in subgroups of non-functioning pituitary neuroendocrine tumours

Astrid Berland Oystese Kristin , Casar-Borota Olivera , Berg-Johnsen Jon , Berg Jens Petter , Bollerslev Jens

Purpose: Clinically Non-Functioning Pituitary Neuroendocrine Tumours (NF-PitNETs) present a varying degree of aggressiveness, and reliable prognostic markers are lacking. We aimed to characterize the distribution of E- and N-cadherin in corticotroph, PIT1 and null-cell NF-PitNETs, and link it to the clinical course of the tumours.Methods: We investigated the distribution of E- and N-cadherin by immunohistochemistry in a retrospective cohort of thirty tum...

ea0090p427 | Pituitary and Neuroendocrinology | ECE2023

Long-term Surgical Remission in Patients with Acromegaly in South-Eastern Norway

Maria Falch Camilla , Kirstine Dupont Anne , Olarescu Cristina , Bollerslev Jens , Berg-Johnsen Jon , Heck Ansgar

Context: Immediate and sustained cure of acromegaly can only be achieved by surgery, however, most growth hormone (GH) producing adenomas are macroadenomas (≥ 10 mm) at diagnosis, with reported surgical cure rates of approximately 50% compared to microadenomas (<10 mm) with an expected higher cure rate (around 80%). Further, long-term data on remission rates after surgery are sparse. Aim: Estimate short- and long-term surgical remission rates o...

ea0090ep770 | Pituitary and Neuroendocrinology | ECE2023

Re-evaluation of MRI in the follow-up of acromegaly – a path towards long-term remission?

Atai Shahriar , Andersen Martin Knudtzon , Bollerslev Jens , Dahlberg Daniel , Wiedmann Markus , Ringstad Geir Andre , Heck Ansgar

Introduction: Remission by complete surgical tumour removal is not achieved in all patients with acromegaly and a subset of patients remain on long-term pharmacological treatment. Repeated surgery or targeted radiation therapy can be considered in patients with residual or recurrent tumour. Identification of residual or recurrent tumour available for surgical treatment can be challenging, and underreporting may lead to a loss in treatment opportunity. The aim of the present st...

ea0063p1109 | Pituitary and Neuroendocrinology 3 | ECE2019

HPA axis function in patients with clinically non-functioning pituitary adenomas: effects of surgery and risk factors for HPA failure

Kolnes Anders Jensen , Oystese Kristin Astrid , Dahlberg Daniel , Bollerslev Jens , Jorgensen Anders Palmstrom

Introduction: Patients planned for first time surgery for clinically non-functioning pituitary adenoma (NFPA) were included in this prospective study.Aims: – To study the prevalence of hypothalamic-pituitary-adrenal (HPA) axis failure preoperatively and 3 months after surgery for clinically NFPA.– To investigate factors predicting risk of HPA axis failure postoperatively.Hypotheses<p class="abst...